2Seventy Cuts Jobs As It Streamlines Pipeline, Focuses On Abecma
CEO Nick Leschly Stepping Down, Remaining As Chairman
Nearly two years after its spin-out from bluebird, 2Seventy is slowing in-house R&D and leaning on partners to conserve cash while BMS-partnered Abecma regains its competitive footing.
You may also be interested in...
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.
Harpoon said it plans to complete the Phase I study of its anti-BCMA immuno-oncology agent HPN217 and use the data to support the next phase of development for the drug.
The drug maker is pointing to potential biweekly dosing as raising the possibility for the bispecific’s use in community oncology, though an expert had said it could take some time for that to happen.